Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Abraxane in Second Line Metastatic Pancreatic Cancer
NCT02242409Phase 2
Key facts
- Status
- Terminated
- Start
- Sep 2014
- Primary completion
- Dec 2016
- Countries
- 1
- Sponsor
- Georgetown University
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Drugs
- nab-paclitaxel
- Conditions
- pancreatic cancer (PC)
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel in pancreatic cancer (PC), sponsored by Georgetown University. Primary endpoint: 4 month progression free survival. Started Sep 2014; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Gemcitabine/abraxane
Gemcitabine and Abraxane combination therapy
03
Who it enrols
Patients with histologically confirmed metastatic adenocarcinoma of the pancreas who have progressed on first-line non-gemcitabine based therapy.
04
Endpoints
Primary
4 month progression free survival
Secondary
Disease control rate
Progression Free Survival
Overall Survival
Beyond the preview
Go deeper on NCT02242409.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02242409.